Skip to main content
Walter Noordzij
dr.

In my profession as a nuclear medicine physician, I’m involved in both clinical and scientific applications of nuclear medicine and radiology modalities. My main interests include haematology, general oncology, radio-immunotherapy, and especially the implementation of new therapeutic strategies. Currently, I have a special interest in imaging post-transplant lymphoproliferative disease, as well as radio-immunotherapy in chemotherapy refractory (non)-Hodgkin’s lymphoma.

Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice.
Published in: Journal of Nuclear Medicine
Access to document 10.2967/jnumed.125.269746 document
223Ra-dichloride ( 223Ra) is an approved therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC) who have symptomatic bone metastases. After an initial course of 6 223Ra injections, treatment may be repeated. The purpose of this study was to evaluate the safety and efficacy of 223Ra retreatment of mCRPC in a real-world population. Methods: This multicenter, retrospective cohort study included patients who had mCRPC and bone metastases who previously received 6 consecutive injections of 223Ra and received at least 1 223Ra retreatment injection between 2014 and 2024....
Joost H H M van Riel, Maarten L Donswijk, Christel Brouwer, Winald R Gerritsen, T T Ha Tan-Phan, Paul W L Thimister, Walter Noordzij, Erik T Te Beek, Laurence J C van Warmerdam, Andries M Bergman, Inge M van Oort, Dirk N J Wyndaele, Maarten J van der Doelen
How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View
Published in: European urology open science
Access to document 10.1016/j.euros.2025.03.007 document
Background and objective: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) and new treatment modalities have expanded the possibilities for diagnosing and managing metastatic prostate cancer, but have also raised questions about their implementation in daily clinical practice. We sought consensus on definitions, preferred imaging modality for staging, and treatment selection in the era of next-generation imaging. Methods: A modified Delphi method involved two voting rounds and a face-to-face multidisciplinary meeting with 40 Dutch prostate cancer (PCa) experts. Consensus was reached if ≥75% of the panellists chose the...
Daniela E. Oprea-Lager, Tessa van Elst, Shafak Aluwini, Els Dewulf, Henk van der Poel, Herman Stoevelaar, Chris H. Bangma, Aart Beeker, Steve Boudewijns, Tom Budiharto, Igle Jan de Jong, Kim C. de Vries, Maarten L. Donswijk, Jurgen J. Fütterer, Paul Hamberg, Linda Heijmen, Robert J. Hoekstra, Thomas M.A. Kerkhofs, Jules Lavalaye, Daphne Luijendijk de BruinWalter Noordzij, Irma M. Oving, Debbie G.J. Robbrecht, Eva E. Schaake, Addy C.M. van de Luijtgaarden, Roderick C.N. van den Bergh, Franchette van den Berkmortel, Tom van der Hulle, Johannes C.K. van der Mijn, Joyce M. van Dodewaard-de Jong, Michel van Kruchten, Pim J. van Leeuwen, Evert van Limbergen, R. Jeroen A. van Moorselaar, Inge M. van Oort, Joep G.H. van Roermund, Robert J. van Soest, Theo Veninga, André N. Vis, Jens Voortman, Peter Paul M. Willemse, Derya Yakar, Niven Mehra
Increased individual workload for nuclear medicine physicians over the past years: 2008-2023 data from The Netherlands
Published in: Annals of Nuclear Medicine
Access to document 10.1007/s12149-024-01995-5 document
OBJECIVE: To investigate temporal trends in the individual workload of nuclear medicine physicians at a large tertiary care academic center between 2008 and 2023. METHODS: This study analyzed the reporting workload of nuclear medicine physicians in a large tertiary care academic center in The Netherlands on 36 unique (randomly sampled) calendar days, for each year between 2008 and 2023. The average daily departmental workload (measured with relative value units) was calculated for each year between 2008 and 2023. The individual workload was calculated by dividing the average daily...
Asaad A H Amasha, Ömer Kasalak, Andor W J M Glaudemans, Walter Noordzij, Rudi A J O Dierckx, Klaas-Pieter Koopmans, Thomas C Kwee
Feasibility of the Absolute Quantification and Left Ventricular Segmentation of Cardiac Sympathetic Innervation in Wild-type Transthyretin Amyloidosis Cardiomyopathy with [123I]-MIBG SPECT/CT: the I-NERVE study.
Published in: Journal of Nuclear Cardiology
Access to document 10.1016/j.nuclcard.2025.102146 document
PURPOSE: Cardiac sympathetic neuronal dysfunction is an early marker in wild-type transthyretin amyloidosis cardiomyopathy (ATTRwt-CM). [ 123I]-MIBG imaging evaluates cardiac sympathetic innervation but lacks volumetric activity quantification in current methods. This study aims to quantify cardiac sympathetic neuronal dysfunction in ATTRwt-CM using [ 123I]-MIBG SPECT/CT and correlate findings with functional and structural cardiac parameters from echocardiogram and cardiac magnetic resonance imaging (CMR). METHODS: We conducted a single-center, descriptive, cross-sectional study to quantify absolute myocardial sympathetic function in ATTRwt-CM using [ 123I]-MIBG SPECT/CT. Retrospective reconstruction allowed for absolute tracer-uptake...
Alwin Tubben, Niek H J Prakken, Oleksandra V Ivashchenko, Hendrea S A Tingen, Andor W J M Glaudemans, Walter Noordzij, Hans L A Nienhuis, Peter van der Meer, Riemer H J A Slart
Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.
Published in: Nature Communications
Access to document 10.1038/s41467-025-66767-9 document
Chimeric antigen receptor T-cell therapy (CART) has revolutionized the treatment of patients with refractory/relapsed large B-cell lymphoma (R/R LBCL). Limited biopsy data indicate that a higher activated CD8 + T-cell density is associated with tumor response. However, tumor biopsies fail to capture the systemic kinetics of CD8 + T-cells. Therefore, we conducted an exploratory phase 2 single-arm trial utilizing a zirconium-89-labeled one-armed anti-CD8α antibody ( 89ZED88082A) to enable whole-body imaging of CD8 + T-cells through positron emission tomography (PET) (NL9034; EUCTR2020-004749-35-NL). Imaging analysis was performed in 23 patients...
Janneke W de Boer, Kylie Keijzer, Jaap A van Doesum, Nienke A M Smit, Adrienne H Brouwers, Joyce van Sluis, Marjolijn N Lub-de Hooge, Frank R Pierik, Gerwin A Huls, Lisanne V van Dijk, Lydia Visser, Arjan Diepstra, Walter Noordzij, Simon P Williams, Alexander Ungewickell, Sjoerd G Elias, Elisabeth G E de Vries, Anne G H Niezink, Tom van Meerten